Unknown

Dataset Information

0

Inhibition of SARS-CoV-2 by type I and type III interferons.


ABSTRACT: The recently emerged severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of the devastating COVID-19 lung disease pandemic. Here, we tested the inhibitory activities of the antiviral interferons of type I (IFN-?) and type III (IFN-?) against SARS-CoV-2 and compared them with those against SARS-CoV-1, which emerged in 2003. Using two mammalian epithelial cell lines (human Calu-3 and simian Vero E6), we found that both IFNs dose-dependently inhibit SARS-CoV-2. In contrast, SARS-CoV-1 was restricted only by IFN-? in these cell lines. SARS-CoV-2 generally exhibited a broader IFN sensitivity than SARS-CoV-1. Moreover, ruxolitinib, an inhibitor of IFN-triggered Janus kinase/signal transducer and activator of transcription signaling, boosted SARS-CoV-2 replication in the IFN-competent Calu-3 cells. We conclude that SARS-CoV-2 is sensitive to exogenously added IFNs. This finding suggests that type I and especially the less adverse effect-prone type III IFN are good candidates for the management of COVID-19.

SUBMITTER: Felgenhauer U 

PROVIDER: S-EPMC7549028 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7495371 | biostudies-literature
| S-EPMC7484541 | biostudies-literature
2021-05-25 | PXD022523 | Pride
| S-EPMC1887573 | biostudies-literature
| S-EPMC5179541 | biostudies-literature
2022-09-18 | GSE190674 | GEO
| S-SCDT-10_15252-EMMM_202216351 | biostudies-other
| S-EPMC7096991 | biostudies-literature
2022-09-19 | GSE190673 | GEO
2022-09-19 | GSE190672 | GEO